Skip to main content
. Author manuscript; available in PMC: 2009 Sep 7.
Published in final edited form as: Stem Cells. 2008 Sep 18;26(12):3027–3036. doi: 10.1634/stemcells.2007-1073

Figure 4. Targeting the Akt Pathway Results in Preferential Induction of CD133+ Cell Apoptosis.

Figure 4

CD133+ and CD133− cells isolated from an established D456MG pediatric glioblastoma xenograft (A, B) or a T3359 glioblastoma patient specimen passaged short-term in immunocompromised mice (C, D) were treated with the indicated concentration of AktIII inhibitor for 24 hours, trypsinized, labeled with an Annexin V kit according to manufacturer's instructions and analyzed by FACS. Apoptosis was induced in CD133+ cells at significantly higher levels than CD133− cells with increasing concentrations of Akt inhibitor. *p<0.001 with ANOVA comparison of AktIII treated CD133+ cells to DMSO control treated CD133+ cells; #, p<0.01 with ANOVA comparison of CD133+ cells to identically treated CD133− cells. Representative FACS gates of CD133+ and CD133− cells from D456MG (B) and T3359 (D) are shown.